Skip to main content

Table 1 Baseline characteristics by group

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

 

MOMH group N = 86

Placebo group N = 87

P Value

Demographics

Gender Female n (%)

65 (75.6)

64 (73.6)

0.862

Age (years) mean (±SD)

57.3 (±10.7)

57.1 (±10.2)

0.955a

Weight (kg) mean (±SD)

74.9 (±13.0)

74.9 (±13.9)

0.995

Height (cm) mean (±SD)

167.4 (±9.6)

167.4 (±9.3)

0.991

BMI (kg/m2) mean (±SD)

26.7 (±4.0)

26.7 (± 4.5)

0.791a

Physiological parameters

Systolic blood pressure (mmHg) mean (±SD)

128.6 (±11.5)

130.0 (±10.3)

0.519a

Diastolic blood pressure (mmHg) mean (±SD)

80.0 (±6.9)

79.0 (±6.2)

0.246a

Heart rate (beats/min) mean (±SD)

71.5 (±6.5)

71.6 (±6.2)

0.934a

Baseline efficacy parameters

NLC frequency (num/week) mean (±SD)

5.4 (±5.0)

6.4 (±8.4)

0.523a

NLC duration (sec/week) mean (±SD)

244.5 (±238.6)

266.5 (±248.9)

0.562a

NLC pain (mean VAS/week) mean (±SD)

6.6 (±1.4)

6.7 (±1.4)

0.584

Sleep quality (mean cumulative score/week) mean (±SD)

13.1 (±3.4)

12.5 (±3.7)

0.327

Quality of life subscales:

- Physical functioning

63.6 (±25.4)

64.8 (±27.5)

0.904a

- Role limitation due to physical health

44.5 (±45.3)

46.6 (±42.7)

0.686a

- Role limitation due to emotional problems

40.7 (±45.0)

40.6 (±43.6)

0.993a

- Vitality

45.9 (±14.5)

45.9 (±12.3)

0.746a

- Mental health

50.1 (±13.6)

49.9 (±11.6)

0.944a

- Social functioning

61.9 (±16.8)

60.1 (±16.3)

0.572a

- Body Pain

47.9 (±17.3)

49.9 (±18.9)

0.640a

- General health

44.9 (±12.1)

45.9 (±9.3)

0.551a

  1. BMI body mass index, MOMH magnesium oxide monohydrate, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale
  2. Note: Variables marked with a were not normally distributed. ANOVA and ANCOVA on ranks were performed for comparisons of these variables